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• Background: Sodium–glucose cotransporter 2 (SGLT2) 
inhibitors are a class of glucose-lowering agents indicated for 
the treatment of type 2 diabetes
– Selectively inhibit renal glucose reabsorption and increase urinary 
glucose excretion (UGE)
• Rationale: Data on the influence of SGLT2 inhibitors on 
electrolyte handling in individuals with type 2 diabetes is 
lacking.
– Due to increased UGE, treatment with SGLT2 inhibitors may result in 
osmotic diuresis, which may trigger volume depletion and dehydration 
affecting electrolyte levels
Introduction
• Why do we care? Electrolyte abnormalities can lead to 
serious complications and even death especially in patients 
with comorbidities such as DM
– Characterize drug class effect 
– Characterize specific drug effect
– Investigate if effects of electrolytes can explain the renal and cardiac 
benefits associated with SGLT2 inhibitors in patients with T2DM 
• Objectives: Meta-analysis of the available evidence to 
examine SGLT2 inhibitors affect on serum electrolyte levels in 




– To what extent, if any, do SGLT2 inhibitors affect 
serum electrolyte levels in patients with type 2 
diabetes mellitus?
• Hypothesis
– Given that SGLT2 inhibitors induce glucosuria and 
osmotic diuresis, we hypothesized that increases 
in circulating electrolyte levels would occur with 
the use of these medications in type 2 diabetics
Approach & Results
• Study design: Database search and subsequent 
meta-analysis of included trials
• Population: Patients with Type 2 Diabetes
• Intervention: SGLT2 Inhibitors
• Comparison group: Placebo




– Weighted mean differences (WMD) (95% CI) in 
serum electrolyte levels were calculated for each 
SGLT2 inhibitor and placebo using a random-
effects model to evaluate each SGLT2 inhibitor 
separately and by dose
– A network meta-analysis with a random-effects 
model was used to compare different SGLT2 
medications
• Performed with STATA v13.1 
Approach & Results
• Results:
– Overall, compared with placebo, SGLT2 inhibitors 
were significantly associated with elevations in 
serum magnesium by 0.08 mmol/L, serum phosphate 
by 0.02 mmol/L, and serum calcium by 0.01 mmol/L. 
– The elevated effect on magnesium was more evident 
for dapagliflozin compared with empagliflozin.
– No statistically detectable differences were evident 
between any other two of SGLT2 inhibitors. 
Approach & Results
• Pairwise: Magnesium Levels
Approach & Results
• Pairwise: Phosphate Levels
Approach & Results
• Pairwise: Potassium Levels
Approach & Results
• Pairwise: Sodium Levels
Approach & Results
• Pairwise: Calcium Levels
Approach & Results
• Pairwise: Urate Levels
Approach & Results
• Network Analysis: Magnesium
Conclusions
• This study suggests that use of SGLT2 
inhibitors increase electrolyte levels to varying 
degrees, with discernible effects on 
magnesium, phosphate, and calcium
• Future investigation is required to assess 
clinical consequences of these effects in T2D 
patients
Future Directions
• Currently updating to include all trials through 
December 2020
– Increase power of study and improve network 
analysis for comparison between SGLT2 inhibitors
• Study does not take into account other 
medications taken by patients with T2DM
Acknowledgements
• Dr. Jingjing Zhang
• Dr. Yonghong Huan
• Dr. Yiqing Song
